A Clinical Observation of 1064-nm Q-Switched Fractional Laser Combined With Oral Tranexamic Acid on Treating of Melasma.
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
1.Melasma is a common acquired condition of symmetric hyperpigmentation, typically occurring
on the face, with higher prevalence in females and darker skin types. Treatments for melasma
include topical, oral, procedural, and combination treatments.
2.1064-nm Q-Switched laser is one of the most widely used lasers for pigmented diseases in
recent years. This wavelength laser can be effectively absorbed by pigment, which leads to
damage of pigment and melanocyte. Previous 1064-nm Q-Switched laser treatment of melasma
requires the use of large flare and low energy scanning repeatedly in the lesion area, and
the terminal reaction is reddish and skin lesion temperature increased by 2℃. So the course
of treatment is even longer and is closely related to the treatment of the doctor's
subjective judgment. Current 1064-nm Q-Switched fractional laser is designed with focusing
lens and can be scanned only once for skin lesions during treatment. Further more, the
treatment energy of a single point is higher and it has stronger ability to destroy melanin.
Finally, 1064-nm Q-Switched fractional laser promotes the expulsion of melanin particles from
the superficial dermis and basal epidermis.
3.Tranexamic acid (TA) works by inhibiting the plasmin-plasminogen pathway. Increase in
plasmin in keratinocytes leads to increase in production of arachidonic acid and
alpha-melanocyte-stimulating hormone (alpha-MSH) production. Thus, by inhibiting the plasmin
pathway, TA results in decreased melanogenesis. Studies support the use of oral TA as an
adjuvant therapy for in refractory cases of melasma or as a second-line or third-line agent,
and there is some early evidence supporting the utility of oral TA as monotherapy. Overall,
randomized controlled trials have found that combination treatment regimens using oral TA as
adjunct therapy results in greater reduction of melasma.
Phase:
N/A
Details
Lead Sponsor:
xjpfW
Collaborators:
Air Force General Hospital of the PLA Chinese Academy of Medical Sciences First Hospital of China Medical University